Vitreous Hemorrhage
29
1
1
19
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 29 trials
100.0%
+13.5% vs benchmark
34%
10 trials in Phase 3/4
26%
5 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 19 completed trials
Clinical Trials (29)
Study on Eye-Brain Cross-Organ Mapping and Systemic Disease Association Based on Multimodal Big Data
Surgical Procedure Efficiency Evaluation stuDy
UNITY VCS Vitreoretinal Surgery
IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes
Clareon Intraocular Lens Stability in Vitrectomy Patients: CLOVE Study
Intraoperative Application of Fluorescein Sodium Angiography in Vascular Retinopathy
Aflibercept Injection for Proliferative Diabetic Retinopathy
Comparison of Restoration in Vitreous Hemorrhage Patients With DME After or Not Removing Inner Limiting Membrane
Performance Comparison of the 25 Gauge 20,000cpm HYPERVIT Dual Blade vs. 10,000cpm ULTRAVIT Vitrectomy Cutter
Combined Vitrectomy and Femtosecond Laser-assisted Cataract Surgery
Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy
Pars Plana Vitrectomy With 25-gauge 20000 Cpm, Bevel-tip Cutter
Performance, Safety and Efficiency Comparison Between 10,000 and 5,000 Cuts Per Minute Vitrectomy Using a 25G Cutter - A Prospective Randomized Controlled Study
Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
Refractive Changes Following Vitrectomy
Oral Sedation in Vitreoretinal Surgery
Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)
Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy
Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy
Different Hemostasis According to the Anesthetic Agents